TerminatedPhase 2NCT01009294

Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)

Studying Becker muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
PTC Therapeutics
Principal Investigator
Leone Atkinson, MD, PhD
PTC Therapeutics
Intervention
Ataluren(drug)
Enrollment
6 enrolled
Eligibility
7 years · MALE
Timeline
20102010

Study locations (6)

Collaborators

Genzyme, a Sanofi Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01009294 on ClinicalTrials.gov

Other trials for Becker muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Becker muscular dystrophy

← Back to all trials